Active Recombinant Mouse Ccl22 Protein
|Product Overview :||Recombinant Mouse Ccl22 protein containing 68 amino acid residues including the four highly conserved cysteine residues present in the CC chemokines without tag was expressed in E.coli.|
- Gene Information
- Related Products
|Description :||MDC is a CC chemokine that is produced in B cells, macrophages, monocyte-derived dendritic cells, activated NK cells and CD4 T cells. It signals through the CCR4 receptor. MDC chemoattracts monocytes, dendritic cells and NK cells, and exerts HIV-suppressive activity.|
|Bio-activity :||Determined by its ability to chemoattract murine BW5147.3 cells using a concentration range of 1-30 ng/mL.|
|Molecular Mass :||7.8 kDa|
|AA Sequence :||GPYGANVEDSICCQDYIRHPLPSRL VKEFFWTSKSCRKPGVVLITVKNRD ICADPRQVWVKKLLHKLS|
|Purity :||≥ 98% by SDS-PAGE gel and HPLC analyses.|
|Notes :||Not for human use.|
|Gene Name :||Ccl22 chemokine (C-C motif) ligand 22 [ Mus musculus (house mouse) ]|
|Official Symbol :||Ccl22|
|Synonyms :||Ccl22; chemokine (C-C motif) ligand 22; MDC; DCBCK; ABCD-1; Scya22; C-C motif chemokine 22; CC chemokine ABCD-1; SMALL INDUCIBLE CYTOKINE A22 PRECURSOR (CC CHEMOKINE ABCD-1) (ACTIVATED B AND DENDRITIC CELL-DERIVED); activated B and dendritic cell-derived; dendritic cell and B cell derived chemokine; small inducible cytokine subfamily A, member 22; small inducible cytokine subfamily A22; small-inducible cytokine A22|
|Gene ID :||20299|
|mRNA Refseq :||NM_009137|
|Protein Refseq :||NP_033163|
|UniProt ID :||O88430|
|◆ Recombinant Protein|
|CCL22-081C||Active Recombinant Human CCL22 Protein (69 aa)||+Inquiry|
|CCL22-082C||Active Recombinant Human CCL22 Protein (68 aa)||+Inquiry|
|CCL22-0627H||Recombinant Human CCL22 Protein, GST-Tagged||+Inquiry|
|CCL22-311H||Recombinant Human CCL22 Protein, His-tagged||+Inquiry|
|Ccl22-2034M||Recombinant Mouse Ccl22 Protein, Myc/DDK-tagged||+Inquiry|
|CCL22-7728HCL||Recombinant Human CCL22 293 Cell Lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The expression of CCL22 gene is regulated by a variety of signaling pathways, including inflammatory factor-mediated signaling pathways, cytokine-mediated signaling pathways, and transcription factors.
Studies have shown that by interfering with the interaction of the CCL22 protein and its receptor CCR4, tumor growth, improve inflammatory response, and regulate autoimmune diseases can be inhibited. These findings provide potential application value for the development of corresponding therapeutic strategies.
A number of inhibitors or antagonists that interact with CCL22 proteins have been developed that block the binding of CCL22 to its receptor CCR4, thereby interfering with its biological function.
The mechanism of action of CCL22 protein in specific diseases can be studied through cell culture experiments, animal models, clinical samples, and related biochemical techniques.
There are complex interactions between CCL22 proteins and other chemokines. They may influence the migration and localization of immune cells by competing for receptors, mutual regulation of expression, etc.
Some studies have shown that in tumor immunotherapy, inhibiting the expression of CCL22 or interfering with its interaction with CCR4 can enhance the effect of immunotherapy and improve the survival rate of patients.
Customer Reviews (3)Write a review
The catalytic activity of CCL22 is very strong, which can significantly improve the selectivity and yield of chemical reactions, and has high application value. -
This repeatability of CCL22 is very good, which can ensure the safety of the experiment and avoid unnecessary risks. -
CCL22 were well suited for our research needs due to their simple storage conditions and long-term preservation. -
Ask a Question for All Ccl22 Products
Required fields are marked with *
My Review for All Ccl22 Products
Required fields are marked with *